LIB-01, also known as DIC-2024 or as Libiguin, is an indirect melanocortin MC<sub>4</sub> receptor potentiator which is under development for the treatment of erectile dysfunction and premature ejaculation. It is taken orally.
The drug works by increasing expression of the melanocortin MC<sub>4</sub> receptor and of its endogenous agonist in the brain. In relation to this, its mechanism of action differs from that of earlier direct melanocortin receptor agonists like bremelanotide. As such, the drug is described as a potential first-in-class medication. LIB-01 produces non-acute long-lasting pro-erectile effects in rodents and humans, with short-term dosing resulting in gradually increasing improvement that is then sustained for weeks despite cessation of dosing. The pro-erectile effects of LIB-01 can be reversed by a melanocortin MC<sub>4</sub> receptor antagonist in rodents.
LIB-01 is a semisynthetic analogue of alkaloids from Neobeguea mahafalensis root bark such as libiguin A and libiguin B. Neobeguea mahafalensis has a long history of traditional use in Madagascar. In 2014, libiguin A and B were discovered via isolation from the roots of the plant and were found to cause "profound enhancement of sexual activity" in rodents. This specifically included having very high potency and a remarkably long-lasting duration in increasing mounting behavior in male rodents.
LIB-01 was originated by Uppsala University and is under development by Dicot Pharma. As of December 2025, it is in phase 2 clinical trials for erectile dysfunction and the preclinical research stage of development for premature ejaculation. The mechanism of action of the drug of indirect melanocortin MC<sub>4</sub> receptor potentiation was not initially disclosed, but was announced by its developer in December 2025. The exact chemical structure of LIB-01 does not yet appear to have been disclosed.